LDN Studies:
6702: Natural History and Structural Functional Relationships in Fabry Renal Disease
6703: Longitudinal Studies of Brain Structure and Function in MPS Disorders
6704: The Natural History of Mucolipidosis type IV
6707: Characterizing the Neurobehavioral Phenotype(s) in MPS III (Pilot Study)
6712: Longitudinal Studies of the Glycoproteinoses
6713: A Natural History Study of Hexosaminidase Deficiency
6714: A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
6716: Genotype - Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis
6718: Gene Therapy for Tay-Sachs Disease. Phase 1: Natural History Data Gather
6719: Immune Response to Intrathecal Enzyme Therapy in Mucopolysaccharidosis 1 Patients
6721: Intravenous N-acetylcysteine for the treatment of Gaucher’s disease and Parkinson’s disease
Diseases Being Studied
- Aspartylglucosaminuria
- Wolman disease
- Cystinosis
- Danon disease
- Fabry disease
- Farber disease
- Fucosidosis
- Gaucher disease
- GM1-Gangliosidosis types I/II/III
- GM2-Gangliosidosis
- alpha-Mannosidosis types I / II
- beta-Mannosidosis
- Metachromatic leukodystrophy
- Sialidosis types I / II
- Mucolipidosis type IV
- Scheie syndrome
- Hunter syndrome
- Sanfilippo syndrome A
- Sanfilippo syndrome B
- Sanfilippo syndrome C
- Sanfilippo syndrome D
- Galactosialidosis types I / II
- Krabbe disease
- Sandhoff disease
- Vogt-Spielmeyer disease
- Hurler syndrome
- Niemann-Pick disease
- I-cell disease
- pseudo-Hurler polydystrophy
- Morquio syndrome
- Maroteaux-Lamy syndrome
- Sly syndrome
- Mucopolysaccharidosis type IX
- Multiple sulfatase deficiency
- Batten disease
- Tay-Sachs disease
- Pompe disease
- Batten disease
- Batten disease, late infantile
- Northern Epilepsy
- Pycnodysostosis
- Schindler disease
- Sialuria, Salla disease
About the Lysosomal Disease Network
www.lysosomaldiseasenetwork.org
Although individually rare "orphan" conditions, the lysosomal diseases collectively affect 1 in 6,000 individuals and are responsible for a significant disability and disease burden. These diseases have become a test bed for some of the most innovative and advanced experimental treatments. The rarity of each lysosomal disease means that no single medical research center has an opportunity to see the entire spectrum, or to acquire sufficient numbers to adequately test new therapies. The combined and integrated efforts of the Lysosomal Disease Network will focus limited resources toward creating a network of centers with expertise in one or more of these diseases in order to solve major challenges in diagnosis, disease management, and therapy. Solutions to these problems will have direct impact on patients suffering from lysosomal diseases, and important implications for medical practice
Refer Patients to the Contact Registry
Download the LDN Contact Registry enrollment form [.pdf]
Contact Information
Chester B. Whitley, PhD, MD David CC Erickson |
Elsa G Shapiro, PhD Brenda Diethelm-Okita |
Participating Clinical Sites
Advocacy
Tay Sachs, Canavan and related genetic diseases
Alpha-mannosidosis and Aspartylglucosaminuria
Cystinosis
Danon Disease
Fabry Disease
Fucosidosis
Gaucher Disease
|
Hide and Seek Foundation
Krabbe disease
Mucolipidosis I (Sialidosis)
Mucolipidosis II/III (I-cell and pseudo-Hurler Polydystrophy)
Mucolipidosis IV
Leukodystrophies
Mucopolysaccharidosis
|
Niemann-Pick Disease
Neuronal ceroid lipofuscinosis (Batten disease)
Pompe Disease
Schindler disease
Wolman Disease
|